The technology has broad applications in the discovery and production of therapeutic monoclonal antibodies. The Trellis proprietary technology, including patents and know-how, uses nanoparticles in a live cell environment to achieve multiplexing and miniaturization in one step. This capability addresses key bottlenecks in the research and discovery process as well as production, such as:

* Elimination of time and resource-intensive cloning and propagation prior to specificity and affinity analysis, and rapid confirmation of clonality after subcloning
* Epitope mapping in a comprehensive, efficient manner to assure targeting of the optimal antigen site
* Resurrection of failed projects through capture of more favorable, but extremely rare specificities
* Selection of high secreting cell populations during manufacturing and scale-up
* Characterization and isolation of antibodies from non-transformed populations, making it possible to find rare, highly specific human monoclonal antibodies in a mixed population of human cells from patients and immune donors